GO
Loading...

Eli Lilly and Co

More

  • Smaller cloud companies chase new business models Monday, 25 Aug 2014 | 12:00 AM ET

    Nothing concentrates minds at a tech start-up like living in the middle of a price war between Amazon and Google. NYT reports.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. The most common inflammatory disease in the United States- it can occur on any part of the body- it is associated with diabetes and heart disease.

  • Lilly psoriasis drug succeeds in late-stage studies Thursday, 21 Aug 2014 | 7:16 AM ET

    Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. Three studies evaluated the drug, ixekizumab, against the generic etanercept and a placebo, in patients with moderate-to-severe plaque psoriasis.

  • Early movers: HD, BHP, BAC, URBN, RDEN, LLY & more Tuesday, 19 Aug 2014 | 7:56 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • SAN FRANCISCO, Aug 14- A group of ex-gaming industry executives say they can use their design chops to solve a major health challenge: Sick patients neglecting to take their medication and costing employers and insurance providers billions of dollars.

  • Aug 14- An Indianapolis church has alleged that JPMorgan Chase& Co mismanaged trust accounts held for its benefit by investing in high cost, risky investments that advanced the firms' interests over its own, according to a lawsuit filed in Indianapolis federal court late on Wednesday.

  • 11 companies spending money to make money Tuesday, 12 Aug 2014 | 10:53 AM ET

    The companies increasing spending on upgrading equipment and facilities are actually investors’ favorites, USA Today reports.

  • Aug 11- Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial. Type 2 diabetes patients are usually given both basal and prandial insulin in a single injection such as Humalog Mix 75/ 25, Biodel said.

  • Biodel's insulin drug found effective in trial Monday, 11 Aug 2014 | 7:30 AM ET

    Aug 11- Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial. The company's shares rose about 10 percent to $2.10 before the bell.

  • *Sanofi, MannKind aim to launch Afrezza in U.S. in Q1 2015. PARIS/ LONDON, Aug 11- French drugmaker Sanofi is betting on inhaled insulin as an alternative option to daily injections for diabetics by signing a worldwide licensing agreement with MannKind Corp worth up to $925 million.

  • *Novo expects to launch in first EU markets in H1 2015. *Shares in Novo rise 1.6 percent. Prospects for degludec- already on sale separately in Europe under the brand name Tresiba- and the new combination with Victoza are critical for Novo, which is the world's biggest insulin maker.

  • US STOCKS-Wall St flat as Caterpillar offsets Facebook Thursday, 24 Jul 2014 | 2:49 PM ET

    *Caterpillar weighs on Dow, Facebook hits record on results. NEW YORK, July 24- U.S. stocks barely budged on Thursday as corporate earnings painted a mixed picture of the economy, though the S&P 500 eked out a record intraday high for the third straight session.

  • *U.S. stocks edge up along with MSCI world index. "The lower-than-expected U.S. initial jobless claims has made people focus on the improving labor market situation," said Ian Lyngen, senior government bond strategist, at CRT Capital in Stamford, Connecticut.

  • NEW YORK, July 24- Major global stock markets edged higher while the euro rose from an eight-month low against the U.S. dollar on Thursday following upbeat euro zone data and stronger-than-expected U.S. earnings.

  • US STOCKS-Results, jobs data buoy Wall St, S&P eyes 2,000 Thursday, 24 Jul 2014 | 10:54 AM ET

    NEW YORK, July 24- The S&P 500 hit a record high for a third straight session on Thursday, lifted by jobs data and earnings, but a weak reading in new home sales kept other key stock indexes little changed.

  • CEOs to Obama: Tax reform, not an inversion Band-Aid Thursday, 24 Jul 2014 | 10:03 AM ET
    President Barack Obama speaks before signing an executive order on workplace discrimination July 21, 2014 at the White House in Washington.

    Obama's support of anti-inversion legislation only aims to put a patch on a larger problem—the need for corporate tax reform, CEOs tell CNBC.

  • July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.

  • *Facebook rallies on results; market value near IBM's. *U.S. manufacturing data due; Europe, China upbeat. NEW YORK, July 24- U.S. stock index futures rose on Thursday, following a record close on the S&P 500 index, lifted by strong job market data in the United States and overseas factory readings, while better than forecast results sent Facebook shares rallying.

  • Ford earnings, jobless claims to lift Wall Street Thursday, 24 Jul 2014 | 8:40 AM ET

    U.S. stock index futures rose on Thursday, ahead of one of the heaviest days for U.S. and European second-quarter earnings.